Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:13:00 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:ADAP from 2023-05-03 to 2024-05-02 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 12:01U:ADAPNews ReleaseAdaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
2024-04-12 08:01U:ADAPNews ReleaseStrategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
2024-03-27 19:31U:ADAPNews ReleaseResults of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
2024-03-06 07:01U:ADAPNews ReleaseAdaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
2024-02-27 08:02U:ADAPNews ReleaseAdaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
2024-02-21 16:02U:ADAPNews ReleaseAdaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
2024-01-31 16:45U:ADAPNews ReleaseAdaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
2024-01-04 07:38U:ADAPNews ReleaseAdaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
2023-12-06 07:01U:ADAPNews ReleaseAdaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
2023-11-29 08:01U:ADAPNews ReleaseAdaptimmune Receives Transfer of IND for Lete-cel Program
2023-11-08 07:31U:ADAPNews ReleaseAdaptimmune Reports Third Quarter Financial Results and Business Update
2023-11-08 07:06U:ADAPNews ReleaseAdaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
2023-10-31 08:01U:ADAPNews ReleaseAdaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
2023-10-31 08:01U:ADAPNews ReleaseAdaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
2023-10-25 08:07U:ADAPNews ReleaseAdaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
2023-10-23 04:16U:ADAPNews ReleaseNext-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
2023-09-11 08:01U:ADAPNews ReleaseDr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
2023-08-09 07:30U:ADAPNews ReleaseAdaptimmune Reports Second Quarter Financial Results and Business Update
2023-08-03 13:25U:ADAPNews ReleaseAdaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
2023-06-01 15:30U:ADAPNews ReleaseAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
2023-05-25 17:01U:ADAPNews ReleaseAdaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
2023-05-12 07:30U:ADAPNews ReleaseAdaptimmune Reports First Quarter Financial Results and Business Update